# Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

> **NCT05534048** · PHASE3 · UNKNOWN · sponsor: **Everest Medicines (Singapore) Pte. Ltd.** · enrollment: 3800 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** PTX-COVID19-B
- **BIOLOGICAL:** Comirnaty®

## Key facts

- **NCT ID:** NCT05534048
- **Lead sponsor:** Everest Medicines (Singapore) Pte. Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-03
- **Primary completion:** 2023-07-02
- **Final completion:** 2023-12-20
- **Target enrollment:** 3800 (ESTIMATED)
- **Last updated:** 2022-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05534048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05534048, "Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05534048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*